GLP-1R agonists do not cause insulin secretion when blood glucose is low, which is why hypoglycemia risk is low compared to older diabetes medications
Food and Drug Administration (FDA) has approved semaglutide (marketed as Wegovy) and Tirzepatide (marketed as Zepbound) specifically for chronic weight management in adults with obesity or overweight individuals with at least one weight-related comorbidity, such as high blood pressure, type 2 diabetes, or high cholesterol
After 8 weeks of treatment, tirzepatide significantly reduced fasting plasma glucose levels, HbA1c levels (a measure of long-term blood sugar control), and body weight compared to the placebo
Weight loss depends on how your body responds, dose tolerance, and consistency rather than the medication alone
Insert the needle at 45-90 degrees
Check the wagering multipliers, the maximum convertible amount, time limits, and the categories that count at full or partial contribution